Cancer Synoptic Reporting Project Group
24 January 2022 at 17:30 UTC
Discussion items
| Item | Description | Owner | Notes | Action |
|---|---|---|---|---|
| 1 | IHC |
| a. her2 in breast tissue
b. her2 in breast cancer from lymph node
c. her2 in breast cancer from any tissue site specimen
| |
| 2 | Treatment effect | Continue discussion: What are we measuring when assessing "treatment effect"? Is this a histologic change? Viability of tumor cells?
| Briefly discussed, but general comments confer that this is a histologic feature property of measure. Will address and confirm at next work group meeting Did not discuss | |
| 3 | Lymph nodes |
2. Management of observables for lymph node involvement. Example: | Great discussion. Assume site specific where clinically called for...use reference materials if provided. | |
| 4 | AJCC update? | Any updates that can be shared? |
Meeting Files
| Attachments |
|---|
Previous Meetings
| Content Report Table | ||||||||
|---|---|---|---|---|---|---|---|---|
|